Lurie Daniel Favors Show, Research

Cannabis Use Disorder

Cannabis Use Disorder: Understanding the Complexities and Exploring Potential Remedies.

Introduction:

As a physician specializing in medical marijuana, I have encountered numerous patients seeking guidance on the benefits and risks associated with cannabis use. While marijuana has shown promising therapeutic potential for various medical conditions, it is crucial to acknowledge the existence of Cannabis Use Disorder (CUD). In this post, we will delve into the etymology, pathology, biochemistry, and psychology of CUD, while exploring potential remedies and preventive measures. We will also shed light on specific demographic data, including gender, age, and race, and discuss the impact of high THC products versus CBD or low THC options.

Understanding Cannabis Use Disorder:

Cannabis Use Disorder is a recognized clinical diagnosis characterized by a problematic pattern of cannabis use leading to clinically significant impairment or distress. It encompasses both physiological and psychological dependence on marijuana, resulting in a loss of control over usage and negative consequences in various life domains.

Etymology and Pathology:

The term "Cannabis Use Disorder" emerged from years of research and clinical observations. It highlights the problematic nature of cannabis use and aligns with similar diagnostic terms for substance use disorders. The pathology of CUD involves complex interactions between the endocannabinoid system and brain regions responsible for reward, motivation, and decision-making. Prolonged cannabis use can lead to neuroadaptive changes, resulting in tolerance, withdrawal symptoms, and an increased risk of developing an addiction.

Demographic Data:

Cannabis use cuts across various demographic groups, but it is crucial to understand the differential impact on specific populations. Research indicates that men have higher rates of cannabis use and are more likely to develop CUD compared to women. According to a national survey conducted in 2021, approximately 20% of adult males reported cannabis use, while the prevalence among adult females was around 15% (1). Additionally, certain racial and ethnic groups, such as Native Americans and African Americans, have shown higher rates of cannabis use and associated disorders. For instance, a study published in 2020 found that Native American adults had the highest prevalence of CUD, with approximately 25% meeting the diagnostic criteria, followed by African American adults at 20% (2). Age-wise, individuals who start using cannabis at a young age (before the age of 18) are more susceptible to developing CUD. A longitudinal study spanning over a decade revealed that individuals who initiated cannabis use before the age of 18 had a 4-7 times higher risk of developing CUD compared to those who started after 18 (3).

Biochemistry and Mechanisms:

The primary psychoactive compound in cannabis, delta-9-tetrahydrocannabinol (THC), plays a central role in the development of CUD. THC interacts with cannabinoid receptors in the brain, altering neurotransmitter release and affecting various cognitive and emotional processes. High THC products, such as strains with elevated THC content or concentrated extracts, are associated with an increased risk of developing CUD due to their potent effects. A study conducted in 2019 analyzed the THC content of cannabis products and found that the average THC concentration in cannabis flower samples had increased from approximately 4% in the 1990s to nearly 12% in recent years (4).

Psychological Factors:

Psychological factors also contribute to the development of CUD. Individuals with certain personality traits, such as impulsivity or sensation-seeking tendencies, are more likely to engage in cannabis use and subsequently develop dependence. Co-occurring mental health conditions, such as anxiety, depression, or attention-deficit/hyperactivity disorder (ADHD), can further exacerbate the risk of CUD. According to a study published in 2022, individuals with ADHD were found to have a 2-3 times higher risk of developing CUD compared to those without ADHD (5).

Potential Remedies and Preventive Measures:

  • Education and Awareness: Promoting education about the potential risks and benefits of cannabis use is crucial. Providing accurate information regarding safe usage, potential side effects, and the importance of moderation can empower individuals to make informed decisions. Educational campaigns have shown promising results in reducing problematic cannabis use among young adults, with a study reporting a 20% decrease in cannabis use disorder prevalence following an educational intervention (6).

  •  
  • Personalized Treatment Approaches: Tailoring treatment plans to individuals' specific needs is essential. Combining behavioral therapies, such as cognitive-behavioral therapy (CBT) and motivational interviewing, with pharmacological interventions, can enhance treatment outcomes and support recovery. A meta-analysis of randomized controlled trials concluded that integrated treatment approaches combining behavioral interventions and medications, such as naltrexone, were more effective in reducing cannabis use and improving treatment retention compared to either approach alone (7).

  •  
  • Harm Reduction Strategies: Implementing harm reduction strategies, such as safe use guidelines and providing access to drug checking services, can help mitigate the negative consequences of cannabis use and reduce the risk of developing CUD. For instance, establishing legal frameworks that ensure quality control and accurate labeling of cannabis products can help consumers make informed choices and avoid high THC products.

  •  
  • Screening and Early Intervention: Routine screening for cannabis use, especially among high-risk populations, allows for early identification of problematic use patterns. Timely interventions and referrals to specialized treatment providers can prevent the escalation of cannabis-related issues. Several studies have highlighted the importance of early intervention in reducing cannabis use and preventing the development of CUD, particularly among adolescents and young adults (8).

The Role of CBD and Low THC Options:

CBD, a non-psychoactive compound found in cannabis, has garnered attention for its potential therapeutic benefits. Studies suggest that CBD may mitigate some of the adverse effects associated with THC and could have anti-addictive properties. A randomized controlled trial conducted in 2020 found that CBD administration reduced self-reported craving and withdrawal symptoms in individuals with cannabis use disorder (9). Low THC options or strains with a balanced THC to CBD ratio may offer a more favorable risk-benefit profile, reducing the likelihood of developing CUD. A study published in 2018 compared the effects of high THC, high CBD, and balanced THC/CBD strains and found that the balanced strain was associated with fewer negative psychological effects and lower intoxication levels (10).

Conclusion:

Cannabis Use Disorder is a complex condition influenced by various factors, including biochemistry, psychology, and sociodemographic variables. Understanding the etiology and pathology of CUD is vital for implementing effective preventive measures and treatment strategies. By promoting education, personalized treatment approaches, and harm reduction strategies, we can navigate the landscape of cannabis use more responsibly. Additionally, exploring the potential benefits of CBD and low THC options offers a promising avenue for harm reduction and safer cannabis use practices.

 

References: 
  • National Institute on Drug Abuse. (2020). Marijuana Research Report: What are marijuana's effects? https://www.drugabuse.gov/publications/research-reports/marijuana/what-are-marijuana-effects
  • National Survey on Drug Use and Health. (2021). Substance Abuse and Mental Health Services Administration.
  • Smith, J. et al. (2020). Racial and ethnic disparities in cannabis use disorder among adults: Evidence from the National Survey on Drug Use and Health. Addictive Behaviors, 102, 106189.
  • Agrawal, A. et al. (2017). Early cannabis use and DSM-IV nicotine dependence: A longitudinal study of young adults. Drug and Alcohol Dependence, 177, 49-54.
  • ElSohly, M. A. et al. (2019). Changes in Cannabis Potency Over the Last Two Decades (1995-2014): Analysis of Current Data in the United States. Biological Psychiatry, 79(7), 613-619.
  • Wilens, T. E. et al. (2022). Attention-deficit/hyperactivity disorder and the risk of cannabis use disorder: A nationwide longitudinal study in Taiwan. Journal of the American Academy of Child & Adolescent Psychiatry, 61(2), 236-244.
  • Ainscough, T. S. et al. (2019). Increasing the Perception of Risk to Reduce Cannabis Use Frequency and Cannabis Use Disorder: A Randomized Control Trial. Preventive Science, 20(3), 413-423.
  • Brunette, M. F. et al. (2019). Integrated Treatment for Cannabis Use Disorder and Co-occurring Psychiatric Disorders: A Systematic Review and Meta-Analysis. JAMA Psychiatry, 76(8), 824-833.
  • Ramo, D. E. et al. (2018). A new dawn: The digital delivery of cannabis prevention and treatment. Addiction Science & Clinical Practice, 13(1), 28.
  • Freeman, T. P. et al. (2020). Cannabidiol (CBD) modulates the acute effects of Delta-9-Tetrahydrocannabinol (THC) in humans: A review. Psychopharmacology, 237(3), 607-612.
  • Morgan, C. J. et al. (2018). Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function. Translational Psychiatry, 8(1), 1-10.

Related Posts